US and UK authorities are monitoring pharmaceutical spending and disclosure in their respective jurisdictions, seeking transparency in the payments pharmaceutical companies make to the healthcare sector.
Payments covered include those made to patient groups, healthcare associations, charities and training providers.
Pfizer’s $60m to DOJ
The US Department of Justice (DOJ)